Syndax Pharmaceuticals Inc represents a strong set of values and corporate philosophy. The company is dedicated to developing innovative therapies that can improve the lives of patients. Syndax strongly believes in collaboration, fostering partnerships to advance their mission. With a commitment to scientific excellence and integrity, Syndax aims to deliver cutting-edge solutions in oncology and other therapeutic areas. By combining their expertise with strategic collaborations, Syndax Pharmaceuticals Inc strives to make a significant impact in the field of healthcare and provide hope for patients worldwide.

Syndax Pharmaceuticals Inc is primarily present in the United States. As a biopharmaceutical company headquartered in Waltham, Massachusetts, Syndax focuses on developing innovative therapies for the treatment of cancer. With a strong presence in the U.S., Syndax Pharmaceuticals Inc is committed to advancing its pipeline and collaborating with key industry stakeholders to bring potential breakthrough treatments to patients in need.

Syndax Pharmaceuticals Inc has achieved several significant milestones in its journey. One of the notable achievements is the successful clinical development of their lead product candidate, entinostat. This drug has shown promising results in treating various types of cancer, particularly advanced breast cancer. Additionally, Syndax Pharmaceuticals has made substantial progress in obtaining regulatory approvals and has initiated collaborations with renowned research institutions and pharmaceutical companies. Overall, Syndax Pharmaceuticals Inc has demonstrated its commitment to innovation and growth in the field of oncology through these remarkable milestones.

Syndax Pharmaceuticals Inc is a biopharmaceutical company with a rich history and background. Founded in 2005, Syndax is dedicated to developing therapies for various cancers. The company has made significant progress in the field of epigenetics, focusing on targeted therapies and innovative drug development. Syndax's commitment to improving patient outcomes and addressing unmet medical needs has driven its success in the industry. With a dedicated team of scientists and researchers, Syndax continues to advance its portfolio of novel therapeutics, providing hope to patients worldwide. This dedication to innovative solutions for cancer treatment has made Syndax Pharmaceuticals Inc a prominent player in the healthcare sector.

The main competitors of Syndax Pharmaceuticals Inc in the market include companies such as Merck & Co. Inc., Bristol-Myers Squibb Company, Roche Holding AG, Pfizer Inc., and Novartis AG.

Syndax Pharmaceuticals Inc is primarily active in the biotechnology and pharmaceutical industries.

The business model of Syndax Pharmaceuticals Inc. revolves around developing and commercializing novel medicines to treat cancer and other diseases. As a biopharmaceutical company, Syndax focuses on developing therapies that target the epigenetic regulation of gene expression, aiming to improve patient outcomes. By leveraging its innovative approach and scientific expertise, Syndax seeks to discover and develop effective treatments to address unmet medical needs. With a focus on precision medicine and personalized therapies, Syndax is committed to advancing the field of medicine and improving the lives of patients worldwide.

KGV za Syndax Pharmaceuticals trenutno ne može biti izračunato.

KUV za Syndax Pharmaceuticals trenutno ne može biti izračunat.

AlleAktien kvalitativni skor za Syndax Pharmaceuticals je 3/10.

Prihod trenutno ne može biti izračunat za Syndax Pharmaceuticals.

Profit trenutno ne može biti izračunat za Syndax Pharmaceuticals.

Syndax Pharmaceuticals Inc. is a biopharmaceutical company based in Waltham, Massachusetts. The company specializes in the development of therapeutics for cancer and pursues an innovative approach to improve treatment options for cancer patients. Syndax Pharmaceuticals' business model is based on several divisions and products, which will be introduced below. 1. Drug Development Syndax Pharmaceuticals focuses on the development of new therapeutics for cancer. The company works closely with leading cancer experts and clinicians to find the best approaches for cancer treatment. The company employs a combination of chemical synthesis and biological methods to develop innovative therapies targeting specific types of cancer. Currently, multiple drug candidates based on epigenetic modulation are in clinical testing at different stages of development. 2. Licensing Syndax Pharmaceuticals also licenses patents and trademarks from other biopharmaceutical companies to expand its product range. The company has established several partnerships with leading companies in the field of oncology, including Merck & Co. and Kyowa Hakko Kirin. Through licensing and collaborations, Syndax Pharmaceuticals can achieve faster and more effective development of new drugs. 3. Product Distribution Syndax Pharmaceuticals utilizes strategic partnerships and distribution channels to place its products in the market. Currently, the company distributes the drug Entinostat, which is in phase III clinical testing. The medication is used in combination with other chemotherapeutics to enhance treatment effectiveness in breast and lung cancer patients. Syndax Pharmaceuticals aims to obtain approval for Entinostat for other types of cancer as well. 4. Intellectual Property Licensing Another important business area for Syndax Pharmaceuticals is the licensing of intellectual property to other companies. The company possesses one of the most comprehensive patent platforms in the field of cancer therapy, including several patents on the combination of Entinostat with other active substances. The strategic focus on IP licensing allows the company to generate additional revenue. In summary, Syndax Pharmaceuticals' business model is based on the development of innovative cancer medications. The company pursues an interdisciplinary approach and collaborates closely with experts and clinicians to maximize treatment efficacy. Through targeted licensing of intellectual property and partnerships with other companies, Syndax Pharmaceuticals advances the development of new therapeutics and contributes to improving treatment options for cancer patients.

Syndax Pharmaceuticals isplaćuje dividendu od 0 USD raspoređenu preko isplata u toku godine.

Dividenda za Syndax Pharmaceuticals trenutno ne može biti izračunata ili kompanija ne isplaćuje dividendu.

ISIN od Syndax Pharmaceuticals je US87164F1057.

WKN od Syndax Pharmaceuticals je A2AFL6.

Oznaka za praćenje akcija kompanije Syndax Pharmaceuticals je SNDX.

U poslednjih 12 meseci, Syndax Pharmaceuticals je isplatio dividendu u iznosu od . To odgovara dividendnom prinosu od oko . Za narednih 12 meseci, Syndax Pharmaceuticals će verovatno isplatiti dividendu od 0 USD.

Dividendski prinos od Syndax Pharmaceuticals trenutno iznosi .

Syndax Pharmaceuticals isplaćuje dividende na kvartalnom nivou. One se isplaćuju u mesecima .

Syndax Pharmaceuticals je isplaćivao dividendu svake godine u poslednjih 0 godina.

Za narednih 12 meseci očekuju se dividende u iznosu od 0 USD. To odgovara dividendnom prinosu od 0 %.

Syndax Pharmaceuticals se svrstava u sektor 'Zdravlje'.

Da biste primili poslednju dividendu od Syndax Pharmaceuticals od 20. 12. 2024. u iznosu od 0 USD, morali ste da imate akciju u depou pre Ex-dana 20. 12. 2024..

Isplata poslednje dividende izvršena je 20. 12. 2024..

U godini 2023 kompanija Syndax Pharmaceuticals je isplatila 0 USD kao dividende.

Dividende od Syndax Pharmaceuticals se isplaćuju u USD.